Table 2. Susceptibility of antimicrobial agents in MRSA isolates.
| Number of isolates for which MIC value was: | |||||
|---|---|---|---|---|---|
| Antimicrobial agents MIC range (μg/mL) | SCCmec type II (N = 43) | SCCmec type III (N = 236) | SCCmec type IV (N = 145) | SCCmec type I-like (1,5B) (N = 38) | p-value* |
| Ciprofloxacin | |||||
| ≤ 1 (S) | - | 3 | 13 | 32 | <0.001 |
| 2 (I) | - | - | 1 | 2 | |
| >2 (I) | 43 | 233 | 131 | 4 | |
| ≥4 (R) | - | - | - | - | |
| Clindamycin | |||||
| ≤0.5 (S) | 4 | 212 | 139 | 36 | <0.001 |
| 1–2 (I) | - | 3 | - | - | |
| >2 (I) | 39 | 21 | 6 | 2 | |
| ≥4 (R) | - | - | - | - | |
| Erythromycin | |||||
| ≤0.5 (S) | - | 1 | 61 | - | <0.001 |
| 1-4(I) | - | - | 5 | 1 | |
| >4 (I) | 43 | 233 | 79 | 37 | |
| ≥8 (R) | - | 1 | - | - | |
| Gentamicin | |||||
| ≤4 (S) | 35 | 3 | 31 | 3 | <0.001 |
| 8 (I) | 1 | - | 4 | 8 | |
| >8 (I) | 7 | 232 | 110 | - | |
| ≥16 (R) | - | - | - | - | |
| Rifampicin | |||||
| ≤ 1 (S) | 39 | 219 | 32 | 29 | <0.001 |
| 2 (I) | - | 3 | - | - | |
| >2 (I) | 3 | 14 | 112 | 1 | |
| ≥4 (R) | - | - | 1 | - | |
| Tetracycline | |||||
| ≤4 (S) | 39 | 6 | 31 | 34 | <0.001 |
| 8 (I) | 1 | 1 | - | 2 | |
| >8 (I) | 3 | 228 | 114 | 2 | |
| ≥16 (R) | - | - | - | - | |
| Trimethoprim/sulfamethoxazole | |||||
| ≤2/38 (S) | 38 | 9 | 28 | 37 | <0.001 |
| ≥4/76 | 4 | 225 | 106 | 1 | |
MIC: Minimum inhibitory concentration.
Interpretation of results was done according to CLSI guidelines [17]; S: susceptible, I: Intermediate resistance, R: Resistant.
*The p-value was calculated between susceptible (S) and the non-susceptible (I and R) isolates collectively.
Multidrug resistance was defined as non-susceptibility to at least one antimicrobial agents in three or more categories [21].